Similar articles

• Establishing guidelines for CAR-T cells: challenges and considerations.

  Wang W, Qin DY, Zhang BL, Wei W, Wang YS, Wei YQ. Wang W, et al. Sci China Life Sci. 2016 Apr;59(4):333-9. doi: 10.1007/s11427-016-5026-5. Epub 2016 Mar 11. Sci China Life Sci. 2016. PMID: 26965523 Review.
• Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.

  Di S, Li Z. Di S, et al. Sci China Life Sci. 2016 Apr;59(4):360-9. doi: 10.1007/s11427-016-5025-6. Epub 2016 Mar 11. Sci China Life Sci. 2016. PMID: 26968709 Review.
• Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.

  Zhang BL, Qin DY, Mo ZM, Li Y, Wei W, Wang YS, Wang W, Wei YQ. Zhang BL, et al. Sci China Life Sci. 2016 Apr;59(4):340-8. doi: 10.1007/s11427-016-5027-4. Epub 2016 Mar 11. Sci China Life Sci. 2016. PMID: 26965525 Review.
• Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.

  Luo C, Wei J, Han W. Luo C, et al. Sci China Life Sci. 2016 Apr;59(4):349-59. doi: 10.1007/s11427-016-5034-5. Epub 2016 Mar 24. Sci China Life Sci. 2016. PMID: 27009301 Review.
• Adoptive therapy with CAR redirected T cells for hematological malignancies.

  Li S, Yang Z, Shen J, Shan J, Qian C. Li S, et al. Sci China Life Sci. 2016 Apr;59(4):370-8. doi: 10.1007/s11427-016-5036-3. Epub 2016 Mar 22. Sci China Life Sci. 2016. PMID: 27009302 Review.